1. Home
  2. INVZ vs EDIT Comparison

INVZ vs EDIT Comparison

Compare INVZ & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INVZ
  • EDIT
  • Stock Information
  • Founded
  • INVZ 2016
  • EDIT 2013
  • Country
  • INVZ Israel
  • EDIT United States
  • Employees
  • INVZ N/A
  • EDIT N/A
  • Industry
  • INVZ Auto Parts:O.E.M.
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • INVZ Consumer Discretionary
  • EDIT Health Care
  • Exchange
  • INVZ Nasdaq
  • EDIT Nasdaq
  • Market Cap
  • INVZ 300.4M
  • EDIT 263.7M
  • IPO Year
  • INVZ N/A
  • EDIT 2016
  • Fundamental
  • Price
  • INVZ $1.66
  • EDIT $2.57
  • Analyst Decision
  • INVZ Buy
  • EDIT Buy
  • Analyst Count
  • INVZ 4
  • EDIT 12
  • Target Price
  • INVZ $2.77
  • EDIT $5.40
  • AVG Volume (30 Days)
  • INVZ 6.9M
  • EDIT 1.7M
  • Earning Date
  • INVZ 08-13-2025
  • EDIT 08-12-2025
  • Dividend Yield
  • INVZ N/A
  • EDIT N/A
  • EPS Growth
  • INVZ N/A
  • EDIT N/A
  • EPS
  • INVZ N/A
  • EDIT N/A
  • Revenue
  • INVZ $37,684,000.00
  • EDIT $38,901,000.00
  • Revenue This Year
  • INVZ $153.64
  • EDIT N/A
  • Revenue Next Year
  • INVZ $91.12
  • EDIT N/A
  • P/E Ratio
  • INVZ N/A
  • EDIT N/A
  • Revenue Growth
  • INVZ 17.32
  • EDIT N/A
  • 52 Week Low
  • INVZ $0.45
  • EDIT $0.91
  • 52 Week High
  • INVZ $3.14
  • EDIT $4.12
  • Technical
  • Relative Strength Index (RSI)
  • INVZ 53.57
  • EDIT 46.57
  • Support Level
  • INVZ $1.64
  • EDIT $2.66
  • Resistance Level
  • INVZ $1.74
  • EDIT $2.78
  • Average True Range (ATR)
  • INVZ 0.13
  • EDIT 0.22
  • MACD
  • INVZ -0.00
  • EDIT -0.02
  • Stochastic Oscillator
  • INVZ 63.16
  • EDIT 39.39

About INVZ Innoviz Technologies Ltd. Ordinary shares

Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: